Evidence map›Paper›PMID 39148034›Full record

ArticleJournal of neurodevelopmental disorders2024

Behavioural and neurodevelopmental characteristics of SYNGAP1.

Nadja Bednarczuk, Harriet Housby, Irene O Lee, Imagine Consortium, David Skuse, Jeanne Wolstencroft

Abstract read
In one paragraph

Article in Journal of neurodevelopmental disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Roadmap to advance therapeutics forTherapeutic advances in rare disease
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nadja BednarczukBehavioural and Brain Sciences Unit, Population, Policy and Practice Department, University College London (UCL) Great Ormond Street Institute for Child Health, 30 Guilford Street, London, WC1N 1EH, UK.
Harriet HousbyBehavioural and Brain Sciences Unit, Population, Policy and Practice Department, University College London (UCL) Great Ormond Street Institute for Child Health, 30 Guilford Street, London, WC1N 1EH, UK.
Irene O LeeBehavioural and Brain Sciences Unit, Population, Policy and Practice Department, University College London (UCL) Great Ormond Street Institute for Child Health, 30 Guilford Street, London, WC1N 1EH, UK.
Imagine ConsortiumBehavioural and Brain Sciences Unit, Population, Policy and Practice Department, University College London (UCL) Great Ormond Street Institute for Child Health, 30 Guilford Street, London, WC1N 1EH, UK.
David SkuseBehavioural and Brain Sciences Unit, Population, Policy and Practice Department, University College London (UCL) Great Ormond Street Institute for Child Health, 30 Guilford Street, London, WC1N 1EH, UK.
Jeanne WolstencroftBehavioural and Brain Sciences Unit, Population, Policy and Practice Department, University College London (UCL) Great Ormond Street Institute for Child Health, 30 Guilford Street, London, WC1N 1EH, UK. j.wolstencroft@ucl.ac.uk.ORCID 0000-0001-6160-9731

Funding

Medical Research Council MR/L011166/1Medical Research Council MR/N022572/1MRF MR/N022572/1
6 · The paper itself

Abstract

backgroundSYNGAP1 variants are associated with varying degrees of intellectual disability (ID), developmental delay (DD), epilepsy, autism, and behavioural difficulties. These features may also be observed in other monogenic conditions. There is a need to systematically compare the characteristics of SYNGAP1 with other monogenic causes of ID and DD to identify features unique to the SYNAGP1 phenotype. We aimed to contrast the neurodevelopmental and behavioural phenotype of children with SYNGAP1-related ID (SYNGAP1-ID) to children with other monogenic conditions and a matched degree of ID.

methodsParticipants were identified from the IMAGINE-ID study, a UK-based, national cohort study of neuropsychiatric risk in children with ID of known genetic origin. Thirteen children with SYNGAP1 variants (age 4-16 years; 85% female) were matched (2:1) with 26 controls with other monogenic causes of ID for chronological and mental age, sex, socio-economic deprivation, adaptive behaviour, and physical health difficulties. Caregivers completed the Development and Wellbeing Assessment (DAWBA) and physical health questionnaires.

resultsOur results demonstrate that seizures affected children with SYNGAP1-ID (84.6%) more frequently than the ID-comparison group (7.6%; p =  < 0.001). Fine-motor development was disproportionally impaired in SYNGAP1-ID, with 92.3% of children experiencing difficulties compared to 50% of ID-comparisons(p = 0.03). Gross motor and social development did not differ between the two groups. Children with SYNGAP1-ID were more likely to be non-verbal (61.5%) than ID-comparisons (23.1%; p = 0.01). Those children able to speak, spoke their first words at the same age as the ID-comparison group (mean = 3.25 years), yet achieved lower language competency (p = 0.04). Children with SYNGAP1-ID compared to the ID-comparison group were not more likely to meet criteria for autism (SYNGAP1-ID = 46.2%; ID-comparison = 30.7%; p = .35), attention-deficit hyperactivity disorder (15.4%;15.4%; p = 1), generalised anxiety (7.7%;15.4%; p = .49) or oppositional defiant disorder (7.7%;0%; p = .15).

conclusionFor the first time, we demonstrate that SYNGAP1-ID is associated with fine motor and language difficulties beyond those experienced by children with other genetic causes of DD and ID. Targeted occupational and speech and language therapies should be incorporated early into SYNGAP1-ID management.

Indexed as

Intellectual Disabilityras GTPase-Activating ProteinsAdolescentChildChild, PreschoolCohort StudiesDevelopmental DisabilitiesEpilepsyFemaleHumansMaleNeurodevelopmental DisordersPhenotypeSeizuresUnited Kingdomras GTPase-Activating ProteinsSYNGAP1 protein, humanAutismBehaviourIntellectual DisabilityNeurodevelopmentSYNGAP1

Identifiers

PMID39148034
PMCPMC11325819

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.